πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 2,465 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12053526

Methods for treatment using anti-alpha4beta7 antibody

Takeda Pharmaceutical Company Limited Β· Granted Tue Aug 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12054553

Immunotherapeutic tumor treatment method

Nektar Therapeutics Β· Granted Tue Aug 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12053531

Materials and methods for treatment of Duchenne Muscular Dystrophy

Vertex Pharmaceuticals Incorporated Β· Granted Tue Aug 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12053455

Antigen-driven detection and treatment of coccidioidomycosis

ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY Β· Granted Tue Aug 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12048699

Cancer treatment methods based on TP53 mutation status and hypermutation

Takeda Pharmaceutical Company Limited Β· Granted Tue Jul 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12043843

Materials and methods for treatment of hemoglobinopathies

Vertex Pharmaceuticals Incorporated Β· Granted Tue Jul 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12042529

Optimization of enzyme replacement therapy for treatment of homocystinuria

The Regents of the University of Colorado, a Body Corporate Β· Granted Tue Jul 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12043601

N-substituted-1H-1,2,4-triazole-3-carboxamides, analogues thereof, and methods of treatmen

The Regents of the University of Colorado Β· Granted Tue Jul 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12042479

Use of topical formulations of cannabinoids in the treatment of epidermolysis bullosa and

INMED PHARMACEUTICALS INC. Β· Granted Tue Jul 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12037363

Peptides for Covid-19 prevention and treatment

SOTIRA COVID, LLC Β· Granted Tue Jul 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12036255

Bacteriophage compositions and methods for treatment of bacterial infections

United States Government as represented by the Department of Veterans Affairs Β· Granted Tue Jul 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12036278

Smallpox vaccine for cancer treatment

Calidi Biotherapeutics (Nevada), Inc. Β· Granted Tue Jul 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12030940

Immunotherapeutic tumor treatment method

Nektar Therapeutics Β· Granted Tue Jul 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12031132

Systems and methods for the treatment of hemoglobinopathies

Editas Medicine, Inc. Β· Granted Tue Jul 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12031136

Treatment for skeletal diseases caused by intracellular protein trafficking defects

The Board of Regents of the University of Oklahoma Β· Granted Tue Jul 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12030869

5-membered heteroaryl carboxamide compounds for treatment of HBV

ASSEMBLY BIOSCIENCES, INC. Β· Granted Tue Jul 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12029732

Treatment of vascular and lymphatic disease

The Regents of the University of Colorado, a Body Corporate Β· Granted Tue Jul 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12029794

Virus-like particle conjugates for diagnosis and treatment of tumors

The United States of America, as represented by the Secretary, Department of Health and Human Serv Β· Granted Tue Jul 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12029755

Carbon monoxide-based therapies and implantable devices for the treatment of vascular dise

THE REGENTS OF THE UNIVERSITY OF MICHIGAN Β· Granted Tue Jul 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12023388

Detection and treatment of caries and microcavities with nanoparticles

THE REGENTS OF THE UNIVERSITY OF MICHIGAN Β· Granted Tue Jul 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 27 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12023348

EGR1 targeting molecules for the treatment of inflammatory and hyperproliferative conditio

The Medical Research, Infrastructure and Health Services Fund of the Tel-Aviv Medical Center Β· Granted Tue Jul 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 27 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12018259

Treatment of liver diseases with cell death inducing DFFA like effector B (CIDEB) inhibito

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jun 25 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12016904

Treatment of gastrointestinal bleeding in patients with severe von Willebrand disease by a

Takeda Pharmaceutical Company Limited Β· Granted Tue Jun 25 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12016948

Micromotors and nanomotors for gastrointestinal diagnosis and treatment applications

The Regents of the University of California Β· Granted Tue Jun 25 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted